Cargando…
Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
Immunotherapy that targets checkpoints, especially programmed cell death protein 1 and programmed cell death ligand 1, has revolutionized cancer therapy regimens. The overall response rate to mono-immunotherapy, however, is limited, emphasizing the need to potentiate the efficacy of these regimens....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337260/ https://www.ncbi.nlm.nih.gov/pubmed/35170503 http://dx.doi.org/10.1097/CM9.0000000000001981 |